ELACESTRANT MONOTHERAPY VS. STANDARD OF CARE FOR
THE TREATMENT OF PATIENTS WITH ER+/HER2- ADVANCED BREAST
CANCER FOLLOWING CDK4/6 INHIBITOR THERAPY: A PHASE 3 RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED, MULTICENTER
TRIAL (EMERALD)

IRB/UVA Tracking #
21310
Contact
Jake Boyd
Contact Email
Contact Phone
1.434.243.0425
Phase
III
Primary purpose
Treatment
Cancer PI
Patrick M Dillon
Status
OPEN TO ACCRUAL
Ages
Adult